PT  - JOURNAL ARTICLE
AU  - Zhang, Xiaodan
AU  - Witteveen-Lane, Martin
AU  - Li, Yanzeng
AU  - Kulkarni, Omkar
AU  - Chesla, Dave
AU  - Chen, Bin
TI  - Comparison of Machine Learning Methods in Mild Cognitive Impairment Prediction for Cancer Patients Using EHR Data
AID  - 10.1101/2023.02.24.23286413
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.24.23286413
4099  - http://medrxiv.org/content/early/2023/02/24/2023.02.24.23286413.short
4100  - http://medrxiv.org/content/early/2023/02/24/2023.02.24.23286413.full
AB  - Cancer and dementia are common in aging populations. Mild cognitive impairment (MCI) is a stage between the cognitive changes of normal aging and dementia that can lead to a decline in quality of life. With the substantial improvement of survival in many cancers, maintaining a high quality of life has become a new goal in cancer care. Identifying those patients with a high risk of developing MCI may facilitate early intervention and further improve patient care. The objective of this study is to survey machine learning techniques and AutoML to model the early detection of MCI in patients with cancers using the features which are known risk factors in dementia and accessible in the electronic health records (EHR). We compared multiple machine learning methods and explored AutoML to predict 1-year risk of MCI for cancer patients. Among 27 models, XGBoost in AutoML gave the highest AUC (0.79), suggesting the superiority of using automated machine learning tools to search for the best model and parameters. The feature importance analysis revealed that cancer patients with brain malignancy, hypertension, or cardiovascular diseases are more likely to develop MCI. The overall poor performance indicates more efforts should be made to improve data quality and increase features and sample size.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research is supported by the MSU-Spectrum Health Alliance funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB) at Corewell Health (SH 2020-071).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript